ClinicalTrials.gg
Not yet recruitingNCT07387003Updated Apr 15, 2026

Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes

A Phase 2 interventional study of GZR101-80 and GZR33 or Insulin degludec/Insulin aspart or Insulin aspart30 (NovoRapid®30) in Type 2 Diabetes (T2DM), sponsored by Gan & Lee Pharmaceuticals.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-15.

Sponsored by Gan & Lee Pharmaceuticals. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
345
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 17 studies in Diabetes Mellitus, Type 2 by Gan & Lee Pharmaceuticals — 6 open to participants now, 9 under way, 1 of them phase 3. Diabetes Mellitus, Type 2 · Gan & Lee Pharmaceuticals.

Planned enrollment
4th of 17
345 · median 92
Started
2026
with 1 other
Phase 2
6 of 17
2 open now
Registered
16th of 17
by date

Among the 17 studies in Diabetes Mellitus, Type 2 by Gan & Lee Pharmaceuticals, this one is the 4th largest by planned enrollment, is one of 2 that started in 2026, is one of 6 in phase 2, and was the 16th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

6 of the 17 studies in Diabetes Mellitus, Type 2 by Gan & Lee Pharmaceuticals are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Diabetes Mellitus, Type 2 by Gan & Lee Pharmaceuticals, or all of them as a file.
02

Study summary

This study will be conducted to evaluate the efficacy and safety of GZR101-80 Injection in patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs or Basal Insulin.

03

Conditions studied

  • Type 2 Diabetes (T2DM)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects sign the Form (ICF) before the study, fully understand the contents, process and possible adverse reactions of the study, and are able to follow the and restrictions specified in this protocol.
  2. At the age of 18-75 (inclusive) at the time of informed consent, male or female.
  3. (BMI) ≥18.5 and ≤35.0 kg/m2 at screening.
  4. According to the diagnostic criteria and classification of diabetes mellitus issued by the World Health Organization (WHO) in 1999, and the supplementary diagnostic criteria recommended by WHO for diagnosis with (HbA1c) (2011), the time to diagnose T2DM is ≥ 180 days at screening.

Exclusion criteria

Exclusion Criteria:

  1. Confirmed or suspected type 1 diabetes mellitus or specific types of diabetes due to other causes (monogenic diabetes, cystic fibrosis, pancreatitis, drug- or chemical-induced diabetes, etc.) prior to screening.
  2. Grade 3 hypoglycemia within 3 months before screening.
  3. Subjects who have any diseases that may affect testing at screening, or subjects who have donated blood, lost more than 400 mL of blood, or received blood transfusion within 3 months prior to screening.
  4. Diagnosis of active malignant tumor within 5 years prior to screening (excluding adequately treated or resected non- basal or squamous cell skin cancer, in situ cancer of cervix, or prostate cancer in situ), or with a high suspicion of potential malignant tumor at screening.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
345 participants (estimated)

Study arms

  • Experimental
    GZR101-80

    Drug: GZR101-80

  • Active comparator
    GZR33 or Insulin degludec/Insulin aspart or Insulin aspart 30 (NovoRapid®30)

    Drug: GZR33 or Insulin degludec/Insulin aspart or Insulin aspart30 (NovoRapid®30)

Interventions

  • DrugGZR101-80

    Administered SC

  • DrugGZR33 or Insulin degludec/Insulin aspart or Insulin aspart30 (NovoRapid®30)

    Administered SC

06

What researchers measure

Primary outcomes

  1. Change in Hemoglobin A1c (HbA1c) from baseline after 16 weeks of treatment.

    Time frame: Baseline , 16 weeks

Secondary outcomes

  1. Change in fasting plasma glucose (FPG) from baseline after 16 weeks of treatment

    Time frame: Baseline , 16 weeks

  2. Safety Endpoints

    Number of adverse events (AEs) and serious adverse events (SAEs), and number and percent

    Time frame: Baseline , 17 weeks

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Feb 2027, 10 months later.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's planned 10 months is below that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2026
First posted
Feb 4, 2026
StartEst.
Apr 10, 2026
Primary completionEst.
Feb 11, 2027
CompletionEst.
Sep 23, 2027
Last update
Apr 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07387003
Responsible party
Sponsor
First posted
Feb 4, 2026
Start date
Apr 10, 2026 (estimated)
Primary completion
Feb 11, 2027 (estimated)
Completion
Sep 23, 2027 (estimated)
Last update
Apr 15, 2026

Study contacts

Wei Zhao
Contact
wei.zhao@ganlee.com
010-8059-5000

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion